Welcome to our dedicated page for SeaStar Medical Holding SEC filings (Ticker: ICU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SeaStar Medical Holding Corporation filings document a medical-device issuer with common stock and publicly listed warrants, registration activity, governance matters, and material events. Securities Act registration statements describe delayed or continuous securities offerings and related capital-structure disclosures, while proxy materials cover annual-meeting voting procedures, board and governance matters, and compensation disclosures.
Current reports on Form 8-K record operating results, QUELIMMUNE and SCD business updates furnished with earnings releases, Nasdaq listing-compliance matters, officer appointments and compensation arrangements, and completed litigation-status disclosures. The filings also frame disclosure topics tied to QUELIMMUNE commercialization, SCD clinical development, FDA post-approval obligations, risk factors, and financing activity.
SeaStar Medical Holding Corporation registered 1,664,543 shares of Common Stock for resale by Lincoln Park Capital Fund, LLC under a resale prospectus; these shares are being offered for resale by the selling stockholder.
The resale is by Lincoln Park and the Company will receive no proceeds from those resales. The Company may, however, receive up to $14,657,887.43 aggregate gross proceeds (in addition to $342,112.57 previously received) under the April 25, 2025 Purchase Agreement if it elects to sell shares to Lincoln Park. As of April 20, 2026, SeaStar had 3,997,002 shares outstanding and Lincoln Park’s purchases are subject to a 4.99% beneficial ownership cap (which Lincoln Park may increase to 9.99% with 61 days’ notice).
SeaStar Medical Holding Corporation reported a quarterly net loss of $3.5 million on $0.5 million of revenue for the three months ended March 31, 2026. Revenue rose from $0.3 million a year earlier as QUELIMMUNE pediatric therapy adoption increased, but spending on research and development ($2.3 million) and general and administrative costs ($1.7 million) kept the company unprofitable.
Cash totaled $9.3 million with total assets of $11.3 million and an accumulated deficit of $155.2 million. Management states that existing cash will not fund operations for at least 12 months, raising substantial doubt about the company’s ability to continue as a going concern. SeaStar highlights ongoing commercialization of QUELIMMUNE, pivotal NEUTRALIZE-AKI and other adult trials, and notes a dismissed securities class action and a pending derivative suit.
SeaStar Medical Holding Corporation reports that, as of March 31, 2026, the reporting parties may be deemed to beneficially own 443,253 shares of Common Stock, representing 9.99% of the class based on 3,993,719 shares outstanding as of March 24, 2026. The reported position consists of four warrants held by Intracoastal exercisable for 134,615, 134,615, 131,062 and 42,961 shares, and excludes additional warrants subject to blocker provisions. Without the blocker provisions, the reporting persons may have been deemed to beneficially own 534,285 shares.
SeaStar Medical reported first quarter 2026 results showing early commercial traction but continued losses. Net revenue reached $0.5 million, up from $0.3 million a year earlier, driven by sales of its QUELIMMUNE pediatric AKI therapy and a 69% year-over-year revenue increase.
The company added seven top-rated children’s hospitals to its QUELIMMUNE customer base and advanced enrollment in the NEUTRALIZE-AKI pivotal trial in adults with acute kidney injury. SeaStar recorded a net loss of $3.5 million, slightly improved from a $3.8 million loss in the prior-year quarter.
Research and development expenses were $2.3 million and general and administrative expenses were $1.7 million, both roughly flat versus last year. Cash was $9.3 million as of March 31, 2026, down from $12.0 million at year-end, reflecting ongoing operating cash use as the company invests in commercialization and its adult AKI trial.
SeaStar Medical Holding Corporation ownership disclosure: Ayrton Capital LLC, Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B, and Waqas Khatri each report beneficial ownership of 278,436 shares of common stock issuable upon exercise of warrants. This holding represents 6.52% of the class based on 3,993,719 shares outstanding as of March 24, 2026. The issuable shares are subject to a 9.99% beneficial ownership blocker. The reported holdings are stated as of March 31, 2026.